Molecular Diagnosis & Therapy

, Volume 14, Issue 2, pp 81–93 | Cite as

The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis

Review Article

Abstract

Systemic and biologic treatments used for the treatment of moderate to severe psoriasis show significant variability in efficacy, are associated with varying degrees of toxicity and, in the case of biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes from these therapies and individualize care for psoriasis patients. Identification of pharmacogenetic and pharmacogenomic markers of treatment response may be useful in predicting clinical response to psoriasis therapies and would help in the development of individually tailored treatment. This would increase the cost effectiveness of treatment and reduce unnecessary exposure to treatment toxicity. This review details the current status of pharmacogenetic and pharmacogenomic markers in psoriasis and explores how these research tools may ultimately lead to safer, more directed treatments. Until now, pharmacogenetic studies in psoriasis have been underpowered to produce reliable results, and many have not recorded treatment response or toxicities prospectively in an objective and reproducible manner. Large-scale collaborations and use of patient registries for systemic and biologic treatments in well characterized patient populations that are uniformly treated and systemically evaluated could play a valuable role in advancing the field of pharmacogenetics and pharmacogenomics of psoriasis.

References

  1. 1.
    Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71PubMedCrossRefGoogle Scholar
  2. 2.
    Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–17PubMedCrossRefGoogle Scholar
  3. 3.
    Horn EJ, Fox KM, Patel V, et al. Association of patient-reported psoriasis severity with income and employment. J Am Acad Dermatol 2007; 57: 963–71PubMedCrossRefGoogle Scholar
  4. 4.
    Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829–35PubMedCrossRefGoogle Scholar
  5. 5.
    Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008; 159Suppl. 2: 2–9PubMedCrossRefGoogle Scholar
  6. 6.
    Spah F. Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 2008; 159Suppl. 2: 10–7PubMedCrossRefGoogle Scholar
  7. 7.
    Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41PubMedCrossRefGoogle Scholar
  8. 8.
    Tiilikainen A, Lassus A, Karvonen J, et al. Psoriasis and HLA-Cw6. Br J Dermatol 1980; 102: 179–84PubMedCrossRefGoogle Scholar
  9. 9.
    Asumalahti K, Veal C, Laitinen T, et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002; 11: 589–97PubMedCrossRefGoogle Scholar
  10. 10.
    Ashumalahti K, Laitinen T, Itkonen-Vatjus R, et al. A candidate gene for psoriasis near HLA-C, HCR, is highly polymorphic with a disease-associated susceptibility allele. Human Mol Genet 2000; 9: 1533–42CrossRefGoogle Scholar
  11. 11.
    Cluster 17 Collaboration. Fine mapping of the psoriasis susceptibility gene PSORS1: a reassessment of risk associated with a putative risk haplotype lacking HLA-Cw6. J Invest Dermatol 2005; 124: 921–30CrossRefGoogle Scholar
  12. 12.
    Nair RP, Duffin KC, Helms C, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet 2009; 41: 199–204PubMedCrossRefGoogle Scholar
  13. 13.
    Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genetics 2006; 78: 827–51CrossRefGoogle Scholar
  14. 14.
    Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 3: e1000041CrossRefGoogle Scholar
  15. 15.
    Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64Suppl. 2: 14–7Google Scholar
  16. 16.
    Vogel F. Modern problem der humangenetik. Ergeb Inn Med U Kinderheilk 1959; 12: 52–125CrossRefGoogle Scholar
  17. 17.
    Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 2000; 356: 1667–71PubMedCrossRefGoogle Scholar
  18. 18.
    International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use [ICH]. Guidance for industry: E15 definitions for genomic biomarkers, pharmacogenomics, pharmacogenetics, genomic data and sample coding categories. Geneva: ICH, 2008 Apr [online]. Available from URL: http://www.fda.gov/RegulatoryInformation/Guidances/ucm129286.htm [Accessed 2010 Feb 6]
  19. 19.
    Bowcock AM, Shannon W, Du F, et al. Insights into psoriasis and other inflammatory disease from large-scale gene expression studies. Hum Mol Genetics 2001; 10: 1793–805CrossRefGoogle Scholar
  20. 20.
    Zhou X, Krueger JG, Kao MC, et al. Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 2003; 13: 69–78PubMedGoogle Scholar
  21. 21.
    Oestreicher JL, Walters IB, Kikuchi T, et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. Pharmacogenomics J 2001; 1: 272–87PubMedCrossRefGoogle Scholar
  22. 22.
    Ito M, Ogawa K, Takeuchi K, et al. Gene expression of enzymes for tryptophan degradation pathway is upregulated in the skin lesions of patients with atopic dermatitis or psoriasis. J Dermatol Sci 2004; 36: 157–64PubMedCrossRefGoogle Scholar
  23. 23.
    Nomura I, Gao B, Boguniewicz M, et al. Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 2003; 112: 1195–202PubMedCrossRefGoogle Scholar
  24. 24.
    Hochberg M, Zeligson S, Amariglio N, et al. Genomic-scale analysis of psoriatic skin reveals differentially expressed insulin-like growth factor-binding protein-7 after phototherapy. Br J Dermatol 2007; 156: 289–300PubMedCrossRefGoogle Scholar
  25. 25.
    Gudjonsson JE, Ding J, Li X, et al. Global gene expression analysis reveals evidence for decreased lipid biosynthesis and increased innate immunity in uninvolved psoriatic skin. J Invest Dermatol 2009; 129(12): 2795–804PubMedCrossRefGoogle Scholar
  26. 26.
    Haider AS, Lowes MA, Suárez-Fariñas M, et al. Identification of cellular pathways of “type 1,” Th17 T cells and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913–20PubMedGoogle Scholar
  27. 27.
    Koczan D, Guthke R, Thiesen HJ, et al. Gene expression profiling of peripheral blood mononuclear leukocytes from psoriasis patients identifies new immune regulatory molecules. Eur J Dermatol 2005; 15: 251–7PubMedGoogle Scholar
  28. 28.
    Batliwalla FM, Li W, Ritchlin CT, et al. Microarray analyses of peripheral blood cells identifies unique gene expression signature in psoriatic arthritis. Mol Med 2005; 11:21–9PubMedCrossRefGoogle Scholar
  29. 29.
    Stoeckman AK, Baechler EC, Ortmann WA, et al. A distinct inflammatory gene expression profile in patients with psoriatic arthritis. Genes Immun 2006; 7: 583–91PubMedCrossRefGoogle Scholar
  30. 30.
    Edmundson WF, Guy WB. Treatment of psoriasis with a folic acid antagonist. Arch Dermatol 1958; 78: 200–3CrossRefGoogle Scholar
  31. 31.
    Fredriksson T, Pettersson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238–44PubMedCrossRefGoogle Scholar
  32. 32.
    Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003; 349: 658–65PubMedCrossRefGoogle Scholar
  33. 33.
    Flytström I, Stenberg B, Svensson A, et al. Methotrexate vs ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116–21PubMedGoogle Scholar
  34. 34.
    van Dooen-Greebe RJ, Kuijpers AL, Mulder J, et al. Methotrexate revisted: effects of long-term treatment in psoriasis. Br J Dermatol 1994; 130: 204–10CrossRefGoogle Scholar
  35. 35.
    Warren RB, Smith RL, Campalani E, et al. Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis. J Invest Dermatol 2008; 128: 1925–9PubMedCrossRefGoogle Scholar
  36. 36.
    Warren RB, Smith RL, Campalani E, et al. Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. Br J Dermatol 2009; 160: 438–41PubMedCrossRefGoogle Scholar
  37. 37.
    Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007; 127: 1860–7PubMedCrossRefGoogle Scholar
  38. 38.
    Mandola MV, Stoehlmacher J, Muller-Weeks S, et al. A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 2003; 63: 2898–904PubMedGoogle Scholar
  39. 39.
    Gusella M, Bolzonella C, Crepaldi G, et al. A novel G/C single-nucleotide polymorphism in the double 28-bp repeat thymidylate synthase allele. Pharmacogenomics J 2006; 6: 421–4PubMedCrossRefGoogle Scholar
  40. 40.
    Andreas K, Häupl T, Lübke C, et al. Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther 2009; 11: R15PubMedCrossRefGoogle Scholar
  41. 41.
    Selga E, Morales C, Noé V, et al. Role of caveolin 1, E-cadherein, enolase 2 and PKCalpha on resistance to methotrexate in human HT29 colon cancer cells. BMC Med Genomics 2008; 1: 35PubMedCrossRefGoogle Scholar
  42. 42.
    Ellis CN, Gorsulowsky DC, Hamilton TA, et al. Cyclosporine improves psoriasis in a double-blind study. J Am Med Assoc 1986; 2256: 3110–6CrossRefGoogle Scholar
  43. 43.
    Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem 1999; 45: 1477–84PubMedGoogle Scholar
  44. 44.
    Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol 2009; 61: 451–85PubMedCrossRefGoogle Scholar
  45. 45.
    Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002; 54: 1271–94PubMedCrossRefGoogle Scholar
  46. 46.
    Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13–33PubMedCrossRefGoogle Scholar
  47. 47.
    Kuhl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–91CrossRefGoogle Scholar
  48. 48.
    Min DI, Ellingrod VL, Marsh S, et al. CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects. Ther Drug Monit 2004; 26: 524–8PubMedCrossRefGoogle Scholar
  49. 49.
    Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–54PubMedCrossRefGoogle Scholar
  50. 50.
    Hesselink DA, van Schaik RH, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74: 245–54PubMedCrossRefGoogle Scholar
  51. 51.
    Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178–81PubMedCrossRefGoogle Scholar
  52. 52.
    Anglicheau D, Thervet E, Etienne I, et al. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004; 75: 422–33PubMedCrossRefGoogle Scholar
  53. 53.
    Hu YF, Tu JH, Tan ZR, et al. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica 2007; 37: 315–27PubMedCrossRefGoogle Scholar
  54. 54.
    Qiu XY, Jiao Z, Zhang M, et al. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol 2008; 64: 1069–84PubMedCrossRefGoogle Scholar
  55. 55.
    Bonhomme-Faivre L, Devocelle A, Saliba F, et al. MDR-1 C3435T polymorphism influences cyclosporine A dose requirement in liver-transplant patients. Transplantation 2004; 78: 21–5PubMedCrossRefGoogle Scholar
  56. 56.
    Yates CR, Zhang W, Song P, et al. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J Clin Pharmacol 2003; 43: 555–64PubMedGoogle Scholar
  57. 57.
    Foote CJ, Greer W, Kiberd B, et al. Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. Transplantation 2007; 83: 1380–4PubMedCrossRefGoogle Scholar
  58. 58.
    Fanta S, Niemi M, Jonsson S, et al. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms. Pharmacogenet Genomics 2008; 18: 77–90PubMedCrossRefGoogle Scholar
  59. 59.
    Koziolek MJ, Riess R, Geiger H, et al. P-glycoprotein in kidney allografts from cyclosporine A treated patients. Kidney Int 2001; 60: 156–66PubMedCrossRefGoogle Scholar
  60. 60.
    Hauser IA, Schaeffeler E, Gauer S, et al. ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 2005; 16: 1501–11PubMedCrossRefGoogle Scholar
  61. 61.
    Hebert MF, Dowling AL, Gierwatowski C, et al. Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 2003; 13: 661–74PubMedCrossRefGoogle Scholar
  62. 62.
    Cebeci I, Kantarci A, Firatli E, et al. Evaluation of the frequency of HLA determinants in patients with gingival overgrowth induced by cyclosporine-A. J Clin Periodontol 1996; 23: 737–42PubMedCrossRefGoogle Scholar
  63. 63.
    Wongpiyabovorn J, Yooyongsatit S, Ruchusatsawat K, et al. Association of the CTG (-278/-460/405) haplotype within the vascular endothelial growth factor gene with early-onset psoriasis. Tissue Antigens 2008; 72: 458–63PubMedCrossRefGoogle Scholar
  64. 64.
    Lee JH, Cho EY, Namkung JH, et al. Single-nucleotide polymorphisms and haplotypes in the VEGF receptor 3 gene and the haplotype GC in the VEGFA gene are associated with psoriasis in Koreans. J Invest Dermatol 2008; 128: 1599–603PubMedCrossRefGoogle Scholar
  65. 65.
    Wang Z, Liang W, Zhang B, et al. Single nucleotide polymorphisms of VEGF gene and psoriasis risk. J Dermatol Sci 2008; 49: 263–5PubMedCrossRefGoogle Scholar
  66. 66.
    Young HS, Summers AM, Read IR, et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. J Invest Dermatol 2006; 126: 453–9PubMedCrossRefGoogle Scholar
  67. 67.
    Campalani E, Allen MH, Fairhurst D, et al. Apolipoprotein E gene polymorphisms are associated with psoriasis but do not determine disease response to acitretin. Br J Dermatol 2006; 154: 345–52PubMedCrossRefGoogle Scholar
  68. 68.
    Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003; 148: 784–8PubMedCrossRefGoogle Scholar
  69. 69.
    Gordon KB, Vaishnaw AK, O’Gorman J, et al. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139: 1563–70PubMedCrossRefGoogle Scholar
  70. 70.
    Haider AS, Lowes MA, Gardner H, et al. Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. J Immunol 2007; 178: 7442–9PubMedGoogle Scholar
  71. 71.
    Keeren K, Friedrich M, Gebuhr I, et al. Expression of tolerance associated gene-1, a mitochondrial protein inhibiting T cell activation, can be used to predict response to immune modulating therapies. J Immunol 2009; 183: 4077–87PubMedCrossRefGoogle Scholar
  72. 72.
    Reich K, Nestle FO, Papp K, et al., EXPRESS Study Investigators. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–74PubMedCrossRefGoogle Scholar
  73. 73.
    Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous versus intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007; 56: 31.e1-15PubMedCrossRefGoogle Scholar
  74. 74.
    Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014–22PubMedCrossRefGoogle Scholar
  75. 75.
    Calabrese LH. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003; 21: 241–8PubMedGoogle Scholar
  76. 76.
    Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106–15PubMedCrossRefGoogle Scholar
  77. 77.
    Mössner R, Kingo K, Kleensang A, et al. Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 2005; 124: 282–4PubMedCrossRefGoogle Scholar
  78. 78.
    Tejasvi T, Stuart P, Nair RP, et al. Preliminary pharmacogenetic assessment of tumour necrosis factor (TNF) polymorphisms in psoriasis: response to anti-TNF and systemic therapies [abstract]. Br J Dermatol 2008; 159: 1391Google Scholar
  79. 79.
    Taylor KD, Plevy SE, Yang H, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001; 120: 1347–55PubMedCrossRefGoogle Scholar
  80. 80.
    Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532–8PubMedCrossRefGoogle Scholar
  81. 81.
    Mugnier B, Balandraud N, Darque A, et al. Polymorphism at postion -308 of the tumour necrosis factor alpha gene influences outcome of inlisimab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849–52PubMedCrossRefGoogle Scholar
  82. 82.
    Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at postion -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005; 64: 793–4PubMedCrossRefGoogle Scholar
  83. 83.
    Seitz M, Wirthmuller U, Moller B, et al. The -308 tumour necrosis factor alpha gene polymorphism predicts therapeutic response to TNF alpha-blockers in rheumatoid arthitis and spondyloarthritis patients. Rheumatology 2007; 46: 93–6PubMedCrossRefGoogle Scholar
  84. 84.
    Guis S, Balandraud N, Bouvenot J, et al. Influence of-308A/G polymorphism in the tumour necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007; 57: 1426–30PubMedCrossRefGoogle Scholar
  85. 85.
    Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. Arthritis Rheum 2004; 50: 1077–82PubMedCrossRefGoogle Scholar
  86. 86.
    Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. Ann Rheum Dis 2006; 65: 342–7PubMedCrossRefGoogle Scholar
  87. 87.
    Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004; 50: 2750–6PubMedCrossRefGoogle Scholar
  88. 88.
    Ryan C, Kelleher J, Collins P, et al. A study to examine if the HLA Cw*0602 allele is a predictor of response to TNF-a inhibitors in the treatment of psoriasis [abstract]. Br J Dermatol 2009; 161Suppl. 1: 28Google Scholar
  89. 89.
    Costanzo A, Talamonti M, Botti E, et al. HLA-Cw6 allele confers susceptibility to efalizumab treatment in psoriasis [abstract]. Br J Dermatol 2008; 159: 1392Google Scholar
  90. 90.
    Gulliver W, Gladney N, MacDonald D, et al. Comorbidities, healthcare utilization and genetics of psoriasis in a founder population [abstract]. Br J Dermatol 2008; 159: 1392CrossRefGoogle Scholar
  91. 91.
    Stingl G, Monnet E, Constanzo A. Identification of genetic risk markers of efalizumab response [abstract]. Br J Dermatol 2008; 159: 1399Google Scholar
  92. 92.
    Leguerre T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res Ther 2006; 8: R105CrossRefGoogle Scholar
  93. 93.
    Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNFalpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 2008; 10: R50–9PubMedCrossRefGoogle Scholar
  94. 94.
    Seitz M, Zwicker M, Villiger PM. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different American College of Rheumatology response groups to methotrexate. J Rheumatol 2003; 30: 2–35Google Scholar
  95. 95.
    Chen ML, Perez A, Sanan DK, et al. Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol 1996; 106: 637–41PubMedCrossRefGoogle Scholar
  96. 96.
    Gross C, Eccleshall T, Malloy P, et al. The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res 1996; 11: 1850–5PubMedCrossRefGoogle Scholar
  97. 97.
    Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? Br J Dermatol 2002; 147: 197–213PubMedCrossRefGoogle Scholar
  98. 98.
    Halsall JA, Osborne JE, Potter L, et al. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibility and prognosis in malignant melanoma. Br J Cancer 2004; 91: 765–70PubMedGoogle Scholar
  99. 99.
    Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/Th2 polarization. Immunol Today 2000; 21: 479–83PubMedCrossRefGoogle Scholar
  100. 100.
    Halsall JA, Osborne JE, Pringle JH, et al. Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics 2005; 15: 349–55PubMedCrossRefGoogle Scholar
  101. 101.
    Dayangac-Erden D, Karaduman A, Erdem-Yurter H. Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res 2007; 299: 487–91PubMedCrossRefGoogle Scholar
  102. 102.
    Saeki H, Asano N, Tsunemi Y, et al. Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris. J Dermatol Sci 2002; 30: 167–71PubMedCrossRefGoogle Scholar
  103. 103.
    Kontula K, Valimaki S, Kaingulainen K, et al. Vitamin D receptor polymorphism and treatment of psoriasis with calcipotriol. Br J Dermatol 1997; 136: 977–8PubMedCrossRefGoogle Scholar
  104. 104.
    Lee DY, Park BS, Choi KH, et al. Vitamin D receptor genotypes are not associated with clinical response to calcipotriol in Korean psoriasis patients. Arch Dermatol Res 2002; 294: 1–5PubMedCrossRefGoogle Scholar
  105. 105.
    Mee JB, Cork MJ. Vitamin D receptor polymorphism and calcipotriol response in patients with psoriasis. J Invest Dermatol 1998; 110: 301–2PubMedCrossRefGoogle Scholar
  106. 106.
    Gabbani G, Pavanello S, Nardini B, et al. Influence of metabolic genotype GSTM1 on levels of urinary mutagens in patients treated topically with coal tar. Mutat Res 1999; 440: 27–33PubMedCrossRefGoogle Scholar
  107. 107.
    Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–74PubMedCrossRefGoogle Scholar
  108. 108.
    Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–84PubMedCrossRefGoogle Scholar
  109. 109.
    Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 (IL-23R) and its ligand (IL-12B) confer protection against psoriasis. Hum Genet 2007; 122: 201–6PubMedCrossRefGoogle Scholar
  110. 110.
    Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273–90PubMedCrossRefGoogle Scholar
  111. 111.
    Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLOS Genet 2008; 4: e10000041Google Scholar
  112. 112.
    Smith RL, Warren RB, Eyre S, et al. Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort. J Invest Dermatol 2008 May; 128(5): 1325–7PubMedCrossRefGoogle Scholar
  113. 113.
    Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053–7PubMedCrossRefGoogle Scholar
  114. 114.
    Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p14 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004; 199: 125–30PubMedCrossRefGoogle Scholar
  115. 115.
    Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol 2006; 176: 1908–15PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Caitriona Ryan
    • 1
  • Alan Menter
    • 1
  • Richard B. Warren
    • 2
  1. 1.Department of DermatologyBaylor Research InstituteDallasUSA
  2. 2.Dermatology Centre, Salford Royal NHS Foundation TrustUniversity of Manchester, Manchester Academic Health Science CentreManchesterUK

Personalised recommendations